Treating HCV prior to liver transplantation

0Citations
Citations of this article
2Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The main goals of treating patients with chronic hepatitis C virus (HCV) infection who are listed for liver transplantation (LT) are: (1) to stabilize disease to reduce the need for LT, (2) to prevent HCV recurrence in the allograft, and (3) to improve graft survival. However, antiviral treatment of HCV-infected patients with advanced disease is limited by poor tolerability and the risk for treatment to increase the risk for hepatic decompensation and even death. Current guidelines suggest that patients with MELD £ 18 could be treated with antiviral therapy by clinicians experienced with treatment in the setting of advanced liver disease [1, 2]. On the basis of the recent OPTN data, more than half of the 5,627 patients infected with HCV currently listed for transplantation have a model for end-stage liver disease (MELD) score of £ 18 and would be potentially eligible for pre-transplant antiviral therapy. In this chapter, we describe the benefi ts and risks of pre-transplant antiviral therapy for HCV-infected patients who are waiting for liver transplantation.

Cite

CITATION STYLE

APA

Martinez-Camacho, A., Fortune, B. E., & Everson, G. T. (2012). Treating HCV prior to liver transplantation. In Chronic Hepatitis C Virus: Advances in Treatment, Promise for the Future (pp. 301–312). Springer New York. https://doi.org/10.1007/978-1-4614-1192-5_24

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free